CD19 and acute lymphoblastic leukemia: To increase bispecific mAb concentration and persistence in the tumor proximity, T cells were transfected with mRNA encoding the CD19-targeting bispecific T cell enganger (BiTE) blinatumomab approved for the treatment of certain types of acute lymphoblastic leukemia (ALL).